Patent · US Active

Method for the treatment of Dravet Syndrome

US12097206B2 · kind B2 · utility

0Cited by

67References

5Claims

0Family size

Assignees

Katholieke Universiteit Leuven · BE
University Hospital Antwerp · BE

Inventors

Berten Ceulemens · Leuven, BE
Lieven Lagae · Oud-Heverlee, BE

Key dates

Filing date	Feb 8, 2022
Grant date	Sep 24, 2024
Priority date	—
Expiry date	Apr 23, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/156
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.